Protocol Ledger

NCT07265947 · Phase II · RECRUITING

Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma

Interventional Phase II clinical trial protocol NCT07265947 sponsored by Tyra Biosciences in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-22 Enrollment: 285 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07265947
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)285 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07265947
Protocol FieldVerified Registry Value
NCT IdentifierNCT07265947
Consolidated Lead SponsorTyra Biosciences
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment285 participants (ESTIMATED)
Registered Start Date2025-12-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI